Determinants of quality of life changes with plasmapheresis in patients with myasthenia gravis

Table 3 Relation between Ach antibodies of the studied patients and QMG and QOL scores

		AchR antibodies		Test value	P value	Sig.
		Negative	Positive	Test value	P value	Sig.
Initial QMG score	Mean ± SD	22.31 ± 3.03	26.46 ± 3.73	−4.126^a	0.000	HS
Initial QMG score	Range	18-27	19-34	−4.126^a	0.000	HS
QMG score after 1 month	Mean ± SD	18.25 ± 2.41	18.00 ± 4.45	0.216^a	0.829	NS
QMG score after 1 month	Range	15-22	11-30	0.216^a	0.829	NS
QMG change	Median (IQR)	−14.86 (−24.08-−9.81)	−32 (−42.31-−20.83)	−3.518^b	0.000	HS
QMG change	Range	−44.44-0	−58.06-0	−3.518^b	0.000	HS
Test value		4.676	9.936	–	–	–
P value		0.001	0.001	–	–	–
Initial QOL score	Mean ± SD	43.25 ± 3.79	47.26 ± 4.79	−3.112^a	0.003	HS
Initial QOL score	Range	37-48	36-57	−3.112^a	0.003	HS
QOL score after 1 month	Mean ± SD	38.44 ± 5.27	38.34 ± 7.03	0.053^a	0.958	NS
QOL score after 1 month	Range	30-48	25-54	0.053^a	0.958	NS
QOL change	Median (IQR)	−11.66 (−17.79-−4.79)	−16.33 (−29.27-−10.42)	−2.218^b	0.027	S
QOL change	Range	−25-4.44	−50-8.16	−2.218^b	0.027	S
Test value		4.839	8.042	–	–	–
P value		0.001	0.001	–	–	–

NS non-significant, S significant, HS highly significant, QOL quality of life, QMG quantitative myasthenia gravis, SD standard deviation, AchR acetylcholine receptors
^aIndependent t test
^bMann-Whitney test